Can Atypical Antipsychotic Augmentation Reduce Subsequent Treatment Failure More Effectively Among Depressed Patients with a Higher Degree of Treatment Resistance? A Meta-Analysis of Randomized Controlled Trials

The International Journal of Neuropsychopharmacology
Hee Ryung WangWon-Myong Bahk

Abstract

Atypical antipsychotic augmentation was demonstrated to be efficacious in treatment-resistant depression (TRD) in previous meta-analyses. We investigate whether there are differences in the effect size of atypical antipsychotic augmentation in major depressive disorder according to the degree of treatment resistance. A comprehensive search of four databases identified 11 randomized controlled trials. The 11 trials, which included 3 341 participants, were pooled using a random-effects meta-analysis. Atypical antipsychotic augmentation of antidepressant therapy showed superior efficacy compared to antidepressant monotherapy in TRD in terms of both response and remission rates (response, risk ratio [RR] = 1.38, 95% confidence interval [CI] = 1.25 to 1.53; remission, RR = 1.62, 95% CI = 1.42 to 1.85). In addition, regarding response rates in the TRD trials, atypical antipsychotic augmentation exhibited significantly different effect sizes according to the degree of treatment resistance (TRD 1: RR = 1.24; TRD 2: RR = 1.37; TRD 2-4: RR = 1.58). In non-TRD trials, atypical antipsychotic augmentation failed to show superior efficacy over antidepressant monotherapy in terms of remission rates (RR = 0.89; 95% CI = 0.69 to 1.14). Atypical...Continue Reading

References

Apr 1, 1979·The British Journal of Psychiatry : the Journal of Mental Science·S A Montgomery, M Asberg
Apr 23, 2003·Biological Psychiatry·Maurizio Fava
Feb 1, 1960·Journal of Neurology, Neurosurgery, and Psychiatry·M HAMILTON
Oct 8, 2004·The International Journal of Neuropsychopharmacology·A Carlo AltamuraEmanuela Mundo
May 14, 2005·The Journal of Clinical Psychiatry·Jordan F KarpEllen Frank
Nov 3, 2007·Annals of Internal Medicine·Ramy A MahmoudGeorges M Gharabawi-Garibaldi
Aug 16, 2008·International Clinical Psychopharmacology·Amir GarakaniJack Hirschowitz
Aug 19, 2009·The American Journal of Psychiatry·J Craig Nelson, George I Papakostas
Jan 7, 2010·JAMA : the Journal of the American Medical Association·Jay C FournierJan Fawcett
Sep 3, 2010·CNS Drugs·Karly P Garnock-Jones, Paul L McCormack
Nov 20, 2010·Current Opinion in Psychiatry·Jun ChenDavid E Kemp
Dec 25, 2010·Database : the Journal of Biological Databases and Curation·Andrei L TurinskyShoshana J Wodak
Jun 1, 2011·Annals of Medicine·Eduard Vieta, Francesc Colom
Mar 1, 2012·Journal of Clinical Psychopharmacology·Fábio Lopes RochaCláudia Hara
Sep 1, 2012·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Elizabeth ChoiMegan J Ehret
Dec 10, 2013·Journal of Affective Disorders·Roger S McIntyreMaia Miguelez
Jan 25, 2014·Psychotherapy and Psychosomatics·Andre F CarvalhoRoger S McIntyre
Mar 5, 2014·CNS Drugs·Michael BauerMaximilian Pilhatsch
Jul 21, 2014·Psychopharmacology·Guillaume FondLaurent Boyer

❮ Previous
Next ❯

Citations

Aug 20, 2016·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Jonathan H HsuDaniel M Blumberger
Nov 17, 2016·International Journal of Psychiatry in Clinical Practice·Markus Dold, Siegfried Kasper
Nov 5, 2015·Development and Psychopathology·Audrey R TyrkaRonald Seifer
Oct 26, 2016·Development and Psychopathology·Audrey R TyrkaStephanie H Parade
Jun 8, 2017·Journal of Clinical Psychopharmacology·Roger S McIntyreJeanette M Jerrell
Dec 27, 2018·Expert Opinion on Investigational Drugs·Renee-Marie RagguettRoger S McIntyre
Aug 9, 2017·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Hee Ryung WangKyung Joon Min
Oct 1, 2016·Chonnam Medical Journal·Sheng-Min WangChi-Un Pae
Aug 23, 2019·Expert Opinion on Pharmacotherapy·Michele FornaroDomenico De Berardis
Nov 30, 2018·Journal of Psychopharmacology·Bettadapura N SrikumarReeba K Vikramadithyan

❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapy

Software Mentioned

STAR
STATA

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here